Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare Biotechnology

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by allinenergy2on Jun 10, 2015 1:06pm

123 Views

Post# 23816336

RE:ATE Level 2

Looks like a cap is in place.

Support is very thin for now, so I'm guessing they're setting up some form of financing in the 15-18 cent
range.

Hopefully somewhere in the middle, and not overly dilutive, but they will need money after Phase 1
validation is complete as they've mentioned in their Presentation.

Drug may have a good chance, but investors here need to understand that it's a very long term process,
but one that a catalyst can move it in a big way, if all goes well with further testing that is.

Thanks for the L2 JR12

Bullboard Posts

Global Tungsten Market and Supply Security